Analysis updated Nov 7, 2026 — scores and signals refreshed daily.
REPLIMUNE GROUP INC (REPL) stock research. Updated Nov 7, 2026. Q-Score 61/100 — Buy. Fair value, forecast, technicals, and insider activity.
Current Q-Score verdict: Buy (61.0) (grade B). 30 signals analyzed (25 differentiated alt-data).
StoQuant's analysis of REPLIMUNE GROUP INC (REPL) is refreshed every trading day. The Q-Score combines discounted cash flow valuation, earnings quality, competitive moat, analyst consensus, ML return forecasts, technical momentum and market sentiment into a single 0–100 composite. Insider transactions from SEC Form 4 filings, the Graham intrinsic value estimate and signal coverage are recomputed as new data arrives, so this page always reflects the latest available information.
REPL stock price is tracked daily for technical and fundamental analysis. The data below shows recent trading activity used in trend analysis, momentum calculation, and entry/exit signals.
| Date | High | Low | Close |
|---|---|---|---|
| 2026-08-10 | $14.12 | $12.27 | $13.67 |
| 2026-08-18 | $15.62 | $14.50 | $15.58 |
| 2026-08-26 | $15.99 | $15.05 | $15.88 |
| 2026-09-03 | $16.02 | $15.02 | $15.29 |
| 2026-09-14 | $13.65 | $12.79 | $13.11 |
| 2026-09-22 | $13.62 | $12.80 | $13.47 |
| 2026-09-30 | $13.66 | $12.65 | $13.24 |
| 2026-10-08 | $13.46 | $12.85 | $13.04 |
| 2026-10-16 | $11.73 | $10.81 | $10.86 |
| 2026-10-26 | $12.57 | $11.36 | $12.47 |
| 2026-11-03 | $21.26 | $19.50 | $20.65 |
How REPLIMUNE GROUP INC stacks up against same-sector peers on market capitalization and alpha scores:
| Ticker | Company | Market Cap | Alpha Score |
|---|---|---|---|
| AZN | AstraZeneca PLC | $290.7B | — |
| NVS | Novartis AG | $287.1B | — |
| NVO | Novo Nordisk A/S | $200.3B | — |
| SNY | Sanofi | $107.6B | — |
| GSK | GSK plc | $102.1B | — |
View all Health Care stocks by valuation and signals →
REPLIMUNE GROUP INC (REPL) scores Buy (61.0), and the composite conceals a 65-point disagreement between its dimensions. It is strongest on ML forecast at 100 and competitive moat at 88, and weakest on analyst consensus at 35. A stock can carry ML forecast that high while analyst consensus sits at 35; the composite averages that tension away, which is why the breakdown is worth reading before the headline number. See Q-Score methodology for how these dimensions are weighted and combined.
| Dimension | Score |
|---|---|
| ML forecast | 100 |
| competitive moat | 88 |
| valuation | 75 |
| technicals | 73 |
| earnings quality | 50 |
| analyst consensus | 35 |
StoQuant analyzes 30 signals (25 alt-data). Alternative data sources (FDA approvals, GitHub activity, SEC filings, App Store ratings) complement traditional financial metrics.
All StoQuant signals are explained in our knowledge base:
Health Care Hub — Top performers and valuation outliers in Health Care
Get daily updates on REPLIMUNE GROUP INC (REPL): Q-Score changes, insider transactions, forecast shifts, sector rotation, and macroeconomic context. The StoQuant digest curates the most material signals for your watchlist — free, no account required.
Browse daily research picks • Unsubscribe anytime • Privacy policy
StoQuant is a quantitative stock research platform powered by AI scoring, fundamental analysis, and IC-weighted signals (live edge on /proof). We cover 3,600+ US-listed equities with daily updates on valuations, earnings quality, insider flow, and ML-based return forecasts. Learn more about us.
Share this stock's latest Q-Score and alpha score on your website, GitHub README, or blog. The SVG badge auto-updates daily:
<a href="https://stoquant.com/research/REPL"><img src="https://stoquant.com/badge/REPL.svg" alt="REPLIMUNE GROUP INC (REPL) Q-Score and Alpha on StoQuant" width="240" height="64" /></a>
StoQuant research is generated algorithmically using public market data, SEC filings, news feeds, and proprietary ML models. Not investment advice. Past performance does not guarantee future results.
Free StoQuant digest by email. No account needed. See today's research picks.